LONDON, August 19, 2019 – George Clinical, a global scientifically-backed clinical research organization (CRO), has expanded its presence in Europe with the opening of a larger and more sophisticated location in the United Kingdom. The office is based in London and compliments the organization’s growing list of global locations throughout the Asia-Pacific region, the United […]
Read MoreIn what could come as a big boost to entrepreneurs working to promote healthcare through innovations across the globe, University of New South Wales—Sydney and The George Institute for Global Health (TGI) have joined forces to launch a program dubbed Health10x designed to accelerate and scale up health focused start-ups. The Health10x program was conceived […]
Read More
George Clinical is pleased to announce that Dr. Bruce Neal has been appointed Executive Director of The George Institute Australia effective September 1. Neal was a founding member of the Institute, together with John Chalmers and Principal Directors Stephen MacMahon and Robyn Norton. Neal has contributed to the growth of the Institute across many areas […]
Read MoreLast year George Clinical gained recognition by the Mandatory Provident Fund (MPF) legislation for their provision of good MPF benefits in Hong Kong. The Mandatory Provident Fund Schemes Authority (MPFA) awarded George Clinical their Good MPF Employer Award at a ceremony in Hong Kong where Evon Hui, Head of Business Operations, East Asia, accepted the […]
Read MoreDecember of 2018 saw the FDA release their “Framework For Evaluating the Potential Use of Real-World Evidence (RWE)” to support the approval of a new indication for a drug already approved under section 505(c) of the FD&C Act. This document was developed to outline guidance and support of real world data collection efforts for post-approval […]
Read MoreGeorge Clinical is proud to have been involved in developing the recently announced recommendations by the Clinical Trial Transformation Initiative (CTTI): The Recommendations for Engaging Patients and Sites in Mobile Clinical Trials. The recommendations, to which George Clinical contributed as a member on the expert committee, aim to help research organizations, sponsors, and other stakeholders […]
Read MoreSYDNEY, May 29, 2019 – George Clinical, a global scientifically-backed clinical research organization (CRO), has again expanded its extensive Asia-Pacific footprint through the opening of a new office in the Philippines. The office is based in the capital city, Manila and compliments the organization’s growing list of global locations. The opening of this office […]
Read MoreSYDNEY, May 15, 2019 – George Clinical, a global scientifically-backed clinical research organization (CRO), has significantly expanded its capabilities in Taiwan having been granted a license to import drugs into the country for clinical trials on behalf of sponsors. The development will be particularly helpful for small to mid-sized clinical trial clients who do not […]
Read MoreSydney, Australia, April 24, 2019 – EPS International Holdings Co., Ltd. (HQ: Tokyo, Japan; Representative Director and President: Hisashi Tanaka; “EPSI” hereafter) and George Clinical Pty Ltd (HQ: Sydney, Australia; Executive Chairman: Glenn Kerkhof; “George Clinical” hereafter) announced today that they have reached an agreement on a strategic partnership that will enhance their combined service offerings […]
Read MoreNoxopharm, a clinical-stage Australian drug development company currently working with George Clinical, is seeking to establish Veyonda®, an innovative dosage formulation of the experimental anti-cancer drug idronoxil, as “an essential adjunct to all forms of radiotherapy in the treatment of prostate cancer, both late-stage and early-stage prostate cancer,” according to an announcement last week. Through […]
Read More
